Institute for Quality and Efficiency in Health Care Dec 20 2024 Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with ( 177 Lu)lutetium vipivotide tetraxetan ("Lutetium-177" for short) is an option. In an early benefit assessment, the Institute for Quality and Efficiency in Health Care (IQWiG) has now